Related references
Note: Only part of the references are listed.Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC
Mei-Mei Zheng et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
Priscilla K. Brastianos et al.
NATURE COMMUNICATIONS (2021)
Original Research Leptomeningeal disease from melanomad-Poor prognosis despite new therapeutic modalities
Eleftheria Chorti et al.
EUROPEAN JOURNAL OF CANCER (2021)
P14.42 Neratinib for treatment of leptomeningeal metastases from HER2-positive breast cancer in extended access program: preliminary results
A Pellerino et al.
NEURO-ONCOLOGY (2021)
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
Jarushka Naidoo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches
Alessia Pellerino et al.
CANCERS (2021)
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
Nikolaj Frost et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer
Kathryn S. Nevel et al.
NEURO-ONCOLOGY (2020)
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
James C. H. Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Myung-Ju Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
Hongyu Xu et al.
ONCOTARGETS AND THERAPY (2020)
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K. Brastianos et al.
NATURE MEDICINE (2020)
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
S. Park et al.
ANNALS OF ONCOLOGY (2020)
Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression
Flora Zagouri et al.
CANCER TREATMENT REVIEWS (2020)
Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient
Richard C. Wu et al.
IMMUNOTHERAPY (2020)
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
Jiyun Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy
Nicholas B. Figura et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD)
Sherise D. Ferguson et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid
Dick Pluim et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2019)
Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis
Elisabeth Gaye et al.
LUNG CANCER (2019)
Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors
Alessia Pellerino et al.
NEUROLOGY (2019)
Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases
Shenpeng Ying et al.
CANCER BIOLOGY & THERAPY (2019)
Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis
Yue Zhao et al.
BMC NEUROLOGY (2019)
Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis
Pedro Exman et al.
NPJ BREAST CANCER (2019)
Leptomeningeal melanoma-A case series in the era of modern systemic therapy
Malmaruha Arasaratnam et al.
PIGMENT CELL & MELANOMA RESEARCH (2018)
Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease
Leomar Y. Ballester et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology
Gaia Griguolo et al.
ONCOLOGIST (2018)
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
Isabella C. Glitza et al.
ESMO OPEN (2018)
Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
Shigeki Nanjo et al.
BRITISH JOURNAL OF CANCER (2018)
Detecting circulating tumor DNA in renal cancer: An open challenge
Claudia Corro et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2017)
Leptomeningeal disease: current diagnostic and therapeutic strategies
Gautam Nayar et al.
ONCOTARGET (2017)
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
Myung-Ju Ahn et al.
LANCET RESPIRATORY MEDICINE (2017)
Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.
Byoung Chul Cho et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis
A. Creemers et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2017)
Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature
Joan How et al.
CLINICAL LUNG CANCER (2017)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
E. Le Rhun et al.
ANNALS OF ONCOLOGY (2017)
Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Use of cell free DNA in breast oncology
Jenna VanLiere Canzoniero et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2016)
Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid
Elena I. Pentsova et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Yang-Si Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging Technologies
Stanislav Volik et al.
MOLECULAR CANCER RESEARCH (2016)
Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies
Parisa Momtaz et al.
ONCOTARGET (2016)
Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
Madeleine Bangham et al.
GYNECOLOGIC ONCOLOGY REPORTS (2016)
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs
Takahisa Kawamura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Leticia De Mattos-Arruda et al.
NATURE COMMUNICATIONS (2015)
A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer
David M. Jackman et al.
ONCOTARGET (2015)
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure
Haihong Yang et al.
TARGETED ONCOLOGY (2015)
Leptomeningeal disease and breast cancer: the importance of tumor subtype
Sausan Abouharb et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
Abenaa M. Brewster et al.
LANCET ONCOLOGY (2014)
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman et al.
NATURE MEDICINE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis
S. Yust-Katz et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer
Eunyoung Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
The Central Nervous System as a Sanctuary Site in ALK-Positive Non-Small-Cell Lung Cancer
Justin F. Gainor et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot et al.
LANCET ONCOLOGY (2013)
Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival
Anna Niwinska et al.
MEDICAL ONCOLOGY (2013)
Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors
Lakshmi Nayak et al.
NEUROLOGY (2013)
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles
Walter W. Chen et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab
I. Bot et al.
JOURNAL OF NEUROLOGY (2012)
Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis
Dolores Subira et al.
NEURO-ONCOLOGY (2012)
Detection of IDH1 mutation in the plasma of patients with glioma
Blandine Boisselier et al.
NEUROLOGY (2012)
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
G. Metro et al.
ANNALS OF ONCOLOGY (2011)
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
Nancy U. Lin et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
Christian Grommes et al.
NEURO-ONCOLOGY (2011)
Leptomeningeal Disease
Morris D. Groves
NEUROSURGERY CLINICS OF NORTH AMERICA (2011)
Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Ticiana Leal et al.
CURRENT CANCER THERAPY REVIEWS (2011)
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases - the UK experience
S. Sutherland et al.
BRITISH JOURNAL OF CANCER (2010)
Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
Paul R. Lockman et al.
CLINICAL CANCER RESEARCH (2010)
Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours
Patrick Beauchesne
LANCET ONCOLOGY (2010)
Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades
Iris Lavon et al.
NEURO-ONCOLOGY (2010)
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Nancy U. Lin et al.
CLINICAL CANCER RESEARCH (2009)
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain
Diane Palmieri et al.
CANCER RESEARCH (2007)
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
David M. Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CSF protein profiling using multiplex immuno-assay
Dieta Brandsma et al.
JOURNAL OF NEUROLOGY (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Leptomeningeal metastasis:: survival and prognostic factors in 155 patients
U Herrlinger et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2004)
Share Paper
